20.500.12556/DiRROS-27745 Prognostic factors and survival outcomes of first CNS relapse in childhood acute lymphoblastic leukemia results from the ALL-IC REL 2016 study Acute lymphoblastic leukemia (ALL) is among the most curable pediatric cancers, yet relapse involving the central nervous system (CNS) remains a major therapeutic obstacle. In this prospective cohort, 97 children (aged 1.1–18.2 years) experiencing their first CNS relapse were enrolled in the ALL-IC REL study. Relapses were classified as isolated CNS (i-CNS, n = 43) or combined CNS (c-CNS, n = 54), and patients received treatment through standard- or high-risk regimens, encompassing chemotherapy, cranial irradiation, and allogeneic stem cell transplantation. The estimated 2-year event-free survival was 40.0%, and overall survival 49.4%, closely matching outcomes reported internationally. Survival rates were comparable across i-CNS and c-CNS relapses, while induction failure occurred more frequently in c-CNS. Multivariable analysis identified female sex, T-cell phenotype, and very early relapse as independent predictors of poor prognosis. These results underscore the critical necessity for risk-adapted therapy techniques and the incorporation of innovative medicines into forthcoming procedures. childhood acute lymphoblastic leukemia central nervous system relapse prognostic factors survival hematopoietic stem cell transplantation akutna limfoblastna levkemija otroci ponovitev bolezni centralni živčni sistem prognostični dejavniki preživetje presaditev hematopoetskih matičnih celic true false true Angleški jezik Slovenski jezik Neznano 2026-02-24 10:25:23 2026-02-24 10:25:24 2026-02-25 03:50:44 0000-00-00 00:00:00 2026 0 0 Nasl. z nasl. zaslona; Opis vira z dne 5. 1. 2026; str. 416-423 no. 2 Vol. 67 2026 0000-00-00 Zaloznikova Objavljeno NiDoloceno 0000-00-00 0000-00-00 0000-00-00 616-053.2 1029-2403 10.1080/10428194.2025.2598861 263367683 RAZ_Hazar_Volkan_2026.pdf RAZ_Hazar_Volkan_2026.pdf 1 B7FB139CC81324B8EB85CF1341B61168 af6f0b09be1f7bfb9d4c2a54a8e5cf249b9dcb73a64fdf36f96fd4aa1f07ec12 edc6b813-1162-11f1-9cb0-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=40767 https://www.tandfonline.com/doi/full/10.1080/10428194.2025.2598861 0 04f72d99-1163-11f1-9cb0-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=40768 Univerzitetni klinični center Ljubljana 0 0 0